Collaboration Agreements in the Life Sciences Tools & Services Industry

26 Contracts & Agreements

Browse by Company

AbCellera Biologics Inc. (1 contract)
Adaptive Biotechnologies Corp (3)
ArcherDX, Inc. (3)
ARQULE INC (1)
Berkeley Lights, Inc. (1)
CM Life Sciences II Inc. (4)
Codex DNA, Inc. (1)
CODEXIS INC (1)
FLUIDIGM CORP (3)
HighCape Capital Acquisition Corp. (2)
NanoString Technologies Inc (2)
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (3)
VG Acquisition Corp. (1)

Recent Contracts

Third Amendment to Collaboration Agreement, dated September 21, 2023, among SomaLogic, Inc., Illumina Cambridge, Ltd., and Illumina, Inc (CM Life Sciences II Inc., Filed With SEC on November 8, 2023)
Third Amendment to Collaboration Agreement, dated as of October 27, 2023, by and between 23andMe, Inc. and GlaxoSmithKline Intellectual Property (No. 3) Limited (VG Acquisition Corp., Filed With SEC on November 8, 2023)
Second Amendment to Collaboration Agreement, dated June 15, 2023, among SomaLogic, Inc., Illumina Cambridge, Ltd. and Illumina, Inc (CM Life Sciences II Inc., Filed With SEC on June 22, 2023)
First Amendment to Collaboration Agreement, dated November 14, 2022, among SomaLogic, Inc., Illumina Cambridge, Ltd. and Illumina, Inc (CM Life Sciences II Inc., Filed With SEC on March 28, 2023)
Protein Engineering Collaboration Agreement, dated as of March 13, 2023, by and between Quantum-Si Incorporated and Protein Evolution, Inc (HighCape Capital Acquisition Corp., Filed With SEC on March 17, 2023)
Amendment No. 2 to Master Collaboration Agreement, dated as of January 4, 2023, by and between SomaLogic Operating Co., Inc. and Novartis Pharma AG (CM Life Sciences II Inc., Filed With SEC on January 10, 2023)
Research Collaboration and License Agreement by and between Registrant and Pfizer Inc. dated December 20, 2021 (Codex DNA, Inc., Filed With SEC on March 23, 2022)
Binders Collaboration Agreement, dated as of September 20, 2021, by and between Quantum-Si Incorporated and Protein Evolution, Inc (HighCape Capital Acquisition Corp., Filed With SEC on November 15, 2021)
Research Collaboration and License Agreement between the Registrant and Eli Lilly and Company, dated March 11, 2020 (AbCellera Biologics Inc., Filed With SEC on November 20, 2020)
Collaboration Agreement, dated as of September 13, 2019, by and between Berkeley Lights, Inc. and Ginkgo Bioworks, Inc (Berkeley Lights, Inc., Filed With SEC on June 26, 2020)
In Vitro Diagnostics Master Collaboration Agreement, dated April 22, 2020, between Registrant and AstraZeneca UK Limited (ArcherDX, Inc., Filed With SEC on June 5, 2020)
Master Collaboration Agreement, dated December 6, 2017, between Registrant and Merck KGaA, Darmstadt, Germany (ArcherDX, Inc., Filed With SEC on June 5, 2020)
IVD Collaboration Agreement, dated May 16, 2016, between Registrant and Illumina, Inc (ArcherDX, Inc., Filed With SEC on June 5, 2020)
Strategic Collaboration and License Agreement, effective as of March 23,202, by and between Codexis, Inc. and Shire Human Genetic Therapies, Inc., a wholly-owned subsidiary of... (CODEXIS INC, Filed With SEC on May 8, 2020)
Amendment #1 to Collaboration Agreement, effective May 28, 2019, between Registrant and Lam Research Corporation (NanoString Technologies Inc, Filed With SEC on March 2, 2020)
Master Collaboration Agreement between Adaptimmune Limited and the Registrant, dated July 10, 2015 (Adaptive Biotechnologies Corp, Filed With SEC on May 30, 2019)
Strategic Collaboration Agreement between Microsoft Corporation and the Registrant, dated December 11, 2017 (Adaptive Biotechnologies Corp, Filed With SEC on May 30, 2019)
Strategic Collaboration and License Agreement between Genentech, Inc. and the Registrant, dated December 19, 2018 (Adaptive Biotechnologies Corp, Filed With SEC on May 30, 2019)
Collaboration Agreement, dated August 4, 2017, between the Registrant and Lam Research Corporation (NanoString Technologies Inc, Filed With SEC on November 8, 2017)
CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION Amendment #1to the Collaboration and Option Agreement dated May 17, 2010 By and between Fluidigm Corporation and Novartis... (FLUIDIGM CORP, Filed With SEC on April 4, 2011)
COLLABORATION AND OPTION AGREEMENT by and between NOVARTIS VACCINES & DIAGNOSTICS, INC. and FLUIDIGM CORPORATION DATE: MAY 17, 2010 (FLUIDIGM CORP, Filed With SEC on February 9, 2011)
COLLABORATION AND OPTION AGREEMENT by and between NOVARTIS VACCINES & DIAGNOSTICS, INC. and FLUIDIGM CORPORATION DATE: MAY 17, 2010 (FLUIDIGM CORP, Filed With SEC on February 2, 2011)
COLLABORATION AGREEMENT between PACIFIC BIOSCIENCES OF CALIFORNIA, INC. and GEN-PROBEINCORPORATED Dated as of June 15, 2010 COLLABORATION AGREEMENT (PACIFIC BIOSCIENCES OF CALIFORNIA, INC., Filed With SEC on October 22, 2010)
COLLABORATION AGREEMENT between PACIFIC BIOSCIENCES OF CALIFORNIA, INC. and GEN-PROBEINCORPORATED Dated as of June 15, 2010 COLLABORATION AGREEMENT (PACIFIC BIOSCIENCES OF CALIFORNIA, INC., Filed With SEC on October 19, 2010)
COLLABORATION AGREEMENT between PACIFICBIOSCIENCES OF CALIFORNIA, INC. and GEN-PROBE INCORPORATED Dated as of June 15, 2010 COLLABORATION AGREEMENT (PACIFIC BIOSCIENCES OF CALIFORNIA, INC., Filed With SEC on September 20, 2010)
AMENDMENT TO COLLABORATION AGREEMENT/ 2/12/2004 (ARQULE INC, Filed With SEC on March 12, 2004)